Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
The ich m7 framework establishes the global standard for identifying, categorizing, and controlling DNA-reactive (mutagenic) impurities in pharmaceuticals. Formally titled Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, the ich m7 guideline applies computational toxicology, bacterial mutagenicity assays, and toxicological thresholds to keep carcinogenic risks negligible.
What it is and who runs it
The ich guideline m7 is an international regulatory standard developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonises technical criteria across regulators in the US, EU, Japan, Canada, and Switzerland.
As described on the official page on 2026-11-11, the current consensus standard is ich m7 r2 (Revision 2), which reached Step 4 harmonisation with addenda containing compound-specific acceptable intakes. In the US, the Food and Drug Administration enforces this framework as formal ich m7 guidance across CDER and CBER. In the EU, the European Medicines Agency applies it through the CHMP. Clinical trial sponsors coordinate these impurity controls alongside Good Clinical Practice (GCP) standards.
Eligibility (summary, with the official source)
Applicability under the ich m7 guidelines depends on the therapeutic modality and clinical development stage, as described on the official page on 2026-11-11:
- In-Scope: New synthetic active pharmaceutical ingredients (APIs), new chemical drug products in clinical development (Phase 1–3), marketing applications (NDA, ANDA), and post-approval manufacturing modifications (such as alternative synthetic routes or raw materials).
- Exclusions: Biological and biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products, herbal medicines, and crude animal or plant extracts.
- Oncology Exceptions: Therapeutics for advanced cancer fall under ICH S9, where life expectancy considerations may adjust standard Threshold of Toxicological Concern (TTC) requirements, in contrast to baseline ratings in the IARC carcinogen classification framework.
What it funds or requires
The ich m7 standard does not distribute grant funding. Instead, it mandates hazard evaluation, computational analysis, and risk controls across five impurity classes.
The Five-Class Hazard Categorisation System
- Class 1 (Known Mutagenic Carcinogens): Impurities with documented mutagenicity and carcinogenicity. Controlled at or below compound-specific acceptable intakes derived from potency metrics (e.g., TD₅₀).
- Class 2 (Known Mutagens with Unknown Carcinogenicity): Ames-positive impurities lacking rodent carcinogenicity data. Controlled at or below default TTC limits.
- Class 3 (Alerting Structure Unrelated to Drug Substance): Impurities with structural alerts for DNA reactivity but no empirical mutagenicity data. Controlled at TTC levels or resolved through an Ames test into Class 5 (negative) or Class 2 (positive).
- Class 4 (Alerting Structure Shared with Drug Substance): Impurities containing alerts identical to those in the parent API or related process intermediates proven non-mutagenic. Controlled under standard ICH Q3A/Q3B qualification limits.
- Class 5 (No Structural Alerts or Demonstrated Non-Mutagenic): Impurities lacking alerts or with alerts disproven by negative Ames assays. Controlled under standard ICH Q3A/Q3B specification thresholds.
Threshold of Toxicological Concern and Daily Intake Limits
For Class 2 and Class 3 impurities lacking compound-specific data, the guideline applies the Threshold of Toxicological Concern (TTC). A lifetime intake of 1.5 µg/day represents an excess lifetime cancer risk of 1 in 100,000 (10⁻⁵). For shorter regimens, sponsors apply Less-Than-Lifetime (LTL) intake limits:
| Treatment Duration | Individual Impurity Limit | Multiple Impurities Limit (≥ 3) |
|---|---|---|
| ≤ 1 month | 120 µg/day | 120 µg/day |
| > 1 month to 12 months | 20 µg/day | 60 µg/day |
| > 1 year to 10 years | 10 µg/day | 30 µg/day |
| > 10 years to lifetime | 1.5 µg/day | 5.0 µg/day |
To convert acceptable daily intake into an active ingredient specification limit in parts per million (ppm), divide by maximum daily dose (MDD):
Concentration Limit (ppm) = Acceptable Intake (µg/day) / Maximum Daily Dose (g/day)
High-potency carcinogens designated as Cohorts of Concern (aflatoxin-like compounds, N-nitrosamines, alkyl-azoxy structures) are excluded from default TTC values and require compound-specific acceptable intakes.
Application or compliance steps
Compliance with ich m7 requires an integrated sequence of analytical, computational, and quality controls:
- Impurity Identification: Map the synthetic pathway, listing raw materials, intermediates, reagents, catalysts, and degradants. Screen container closures through extractables and leachables risk assessments.
- Dual (Q)SAR Evaluation: Screen structures using two complementary (Q)SAR models: one rule-based engine and one statistical engine. If both predict negative, classify as Class 5.
- Expert Review and Ames Testing: When (Q)SAR models conflict or flag alerts, conduct toxicological expert review. If ambiguity persists for a Class 3 alert, perform an OECD 471 Ames test.
- Acceptable Intake Determination: Establish clinical exposure duration and apply the corresponding lifetime TTC or LTL threshold, observing multi-impurity cumulative caps.
- Control Strategy Selection: Implement one of four options:
- Option 1: Release testing on the drug substance against the calculated ppm limit.
- Option 2: Specification testing at an intermediate or raw material stage.
- Option 3: Intermediate testing combined with demonstrated spike-and-purge clearance factors.
- Option 4: Process understanding and fate-and-purge justification without routine testing.
- Dossier Submission: Compile findings in CTD Module 2.3 and Module 3.2.S, submitting via the FDA Electronic Submissions Gateway (ESG) or regional equivalents.
Typical timeline phases (no calendar dates as facts)
Implementation of ich m7 proceeds across standard development phases:
- Route Scouting and Pre-IND: Synthetic pathways are screened in silico to avoid mutagenic materials, producing initial hazard logs.
- Phase 1 and 2 Clinical Trials: Initial specifications use short-term LTL limits (e.g., ≤ 1 month or ≤ 1 year) in investigational filings, with clinical trial protocols cataloged in ClinicalTrials.gov reporting registries.
- Phase 3 and Validation: Commercial synthetic routes are locked, lifetime TTC limits are established, and spike-and-purge clearance studies validate Option 3 or Option 4 controls.
- Marketing Authorization: Regulators audit computational reports, Ames data, and analytical clearance validations during NDA or MAA review.
- Post-Approval Life Cycle: Manufacturing modifications trigger change-control assessments to ensure qualified impurity profiles remain valid.
Common mistakes
Regulatory reviewers frequently identify recurring compliance errors:
- Using a Single (Q)SAR Engine: Relying on only one computational tool violates the requirement for dual complementary (rule-based and statistical) systems.
- Applying Default TTC to Cohorts of Concern: Controlling nitrosamines or aflatoxins under the default 1.5 µg/day TTC leads to regulatory rejection; compound-specific limits are mandatory.
- Ignoring Degradation Products: Focusing exclusively on synthetic intermediates while neglecting shelf-life degradation products or packaging interactions.
- Unsupported Option 4 Claims: Asserting fate-and-purge clearance without experimental data, kinetic measurements, or robust reactivity arguments.
- Omitting Cumulative Limits: Setting isolated limits for multiple mutagenic impurities without observing the 5.0 µg/day cumulative lifetime cap.
Related programs
The table below summarizes how the ich m7 framework interacts with related pharmaceutical standards:
| Standard / Guideline | Governing Body | Primary Technical Scope | Relationship to ICH M7 |
|---|---|---|---|
| ICH M7(R2) | ICH / Global Regulators | DNA-reactive mutagenic impurities in pharmaceuticals | Primary benchmark for mutagenic hazard assessment and TTC control. |
| ICH Q3A(R2) | ICH | Impurities in new drug substances | Governs general non-mutagenic organic impurities; Class 4 and 5 impurities defer to Q3A. |
| ICH Q3B(R2) | ICH | Impurities in new drug products | Establishes thresholds for non-mutagenic degradation products in finished dosage forms. |
| ICH Q3C(R8) | ICH | Residual solvents in pharmaceuticals | Provides Permitted Daily Exposures (PDE) for processing solvents used in drug manufacture. |
| ICH Q3D(R2) | ICH | Elemental impurities in drug products | Defines toxicological exposure limits for metallic and elemental catalysts and contaminants. |
| ICH S9 | ICH | Nonclinical evaluation for anticancer pharmaceuticals | Provides regulatory flexibility regarding mutagenic impurity limits in terminal oncology settings. |
FAQ
What is the primary purpose of the ich m7 guideline?
The primary purpose of the ich m7 guideline is to establish a harmonised framework for assessing and controlling DNA-reactive (mutagenic) impurities in pharmaceuticals, keeping cancer risks below 1 in 100,000.
How do ich m7 guidelines classify mutagenic impurities?
The ich m7 guidelines classify impurities into five hazard tiers: Class 1 (known mutagenic carcinogens), Class 2 (known mutagens with unknown carcinogenicity), Class 3 (alerting structures with no experimental data), Class 4 (alerts shared with drug substance and non-mutagenic), and Class 5 (no alerts or verified non-mutagenic).
What is the lifetime Threshold of Toxicological Concern (TTC) under ich m7 guidance?
Under formal ich m7 guidance, the default lifetime Threshold of Toxicological Concern for an individual mutagenic impurity is 1.5 µg/day, representing a 10⁻⁵ excess cancer risk over a 70-year lifespan.
What updates were introduced in ich m7 r2?
The ich m7 r2 revision updated the core guideline text and expanded application addenda with compound-specific acceptable intakes for commonly encountered mutagenic impurities like alkyl halides and aromatic amines.
How are Less-Than-Lifetime (LTL) limits applied during clinical trials?
Less-Than-Lifetime (LTL) limits permit higher daily intakes during short-term exposures, such as early clinical trials. For durations of one month or less, the intake limit rises to 120 µg/day based on cumulative toxicological dose.
Sources
- International Council for Harmonisation (ICH). ICH Harmonised Guideline: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R2). Step 4 version, dated 3 April 2023. Available at: https://database.ich.org/sites/default/files/ICH_M7_R2_Guideline_Step4_2023_0216_1.pdf (Official index: https://www.ich.org/page/multidisciplinary-guidelines). Checked November 11, 2026.
- US Food and Drug Administration (FDA). M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk: Guidance for Industry. CDER/CBER, July 2023. Docket FDA-2014-D-2138. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential. Checked November 11, 2026.
- European Medicines Agency (EMA). ICH guideline M7(R2) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Scientific guideline. CHMP, EMA/CHMP/ICH/83812/2013, November 2023. Available at: https://www.ema.europa.eu/en/ich-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-scientific-guideline. Checked November 11, 2026.







